Hormonal Treatment

Tamoxifen and endometrial cancer – pro

Tamoxifen is a venerable drug that revolutionized breast cancer care when it was first introduced. More recently, it has been largely supplanted by aromatase inhibitors(AI), but tamoxifen is still useful in pre-menopausal women, in whom AIs do not work. Tamoxifen has a variety of bothersome side effects, related mostly to forced early menopause. In addition, a rare complication of tamoxifen is uterine lining overgrowth, which can proceed to endometrial

Read more
Faslodex for breast cancer – pro

(Faslodex)Fulvestrant is a selective estrogen receptor down-regulator (SERD). It acts not by competing with estrogen at the estrogen receptors, but by selectively down modulating it and causing it to be degraded and disappear.  Fulvestrant is indicated for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. It used to be thought that this unique mechanism

Read more
Generic Versus Brand Name Aromasin – pro

Brand-name Aromasin is manufactured by Pfizer, Inc. However, the patent for this medicine has expired in early 2012, and it is now available in generic form. Aromasin is available in generic form in one strength: exemestane 25 mg tablets. Generic Aromasin is made by Roxane Laboratories, Inc., and Greenstone LLC. The version made by Greenstone is an "authorized generic," which means that it is actually made by Pfizer and is actually the real, brand-name

Read more
Tamoxifen, Endometrium and Hysterectomy – pro

Tamoxifen has different effects on different tissues. Whereas it blocks estrogen in the breast, it has pro- estrogenic effects on bone and in the uterus. Working as an estrogen-like substance, it can cause dysfunctional uterine bleeding and endometrial thickening and very rarely, superficial, easily treatable, endometrial cancer and sarcoma.  In a review of all NSABP breast cancer treatment trials, the rate of sarcoma in women treated with tamoxifen

Read more
Herceptin and Arimidex for HER+, ER/PR+ Metastatic Breast Cancer – pro

Preclinical evidence suggests Herceptin can restore and amplify responsiveness to hormonal therapy. The combination of Tykerb and Femara is FDA approved and is thought to work through this mechanism. A randomized phase III TAnDEM studyinvestigated Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor in receptor 2-positive, hormone receptor-positive metastatic breast

Read more

Fatal error: Call to undefined function fw_blog_pagination() in /home/content/43/9379243/html/wp-content/themes/wisdom/blog_category.php on line 39